Jeffrey P. Meyers

5.7k total citations · 1 hit paper
40 papers, 1.4k citations indexed

About

Jeffrey P. Meyers is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Jeffrey P. Meyers has authored 40 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 13 papers in Pathology and Forensic Medicine. Recurrent topics in Jeffrey P. Meyers's work include Colorectal Cancer Treatments and Studies (23 papers), Genetic factors in colorectal cancer (11 papers) and Lung Cancer Treatments and Mutations (9 papers). Jeffrey P. Meyers is often cited by papers focused on Colorectal Cancer Treatments and Studies (23 papers), Genetic factors in colorectal cancer (11 papers) and Lung Cancer Treatments and Mutations (9 papers). Jeffrey P. Meyers collaborates with scholars based in United States, France and United Kingdom. Jeffrey P. Meyers's co-authors include Daniel J. Sargent, Qian Shi, Axel Grothey, Aimery de Gramont, Michel Seymour, Leonard B. Saltz, Tim Maughan, Christophe Tournigand, Benoist Chibaudel and Joseph Moen and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Jeffrey P. Meyers

38 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

2016 434 citations Jan Franko, Qian Shi et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey P. Meyers United States	17	863	528	408	317	207	40	1.4k
Geert-Jan Creemers Netherlands	15	907 1.1×	489 0.9×	376 0.9×	191 0.6×	250 1.2×	44	1.4k
Garth D. Nelson United States	16	1.1k 1.2×	533 1.0×	280 0.7×	716 2.3×	135 0.7×	42	1.7k
Felice N. van Erning Netherlands	23	997 1.2×	597 1.1×	416 1.0×	209 0.7×	94 0.5×	90	1.5k
G.J. Creemers Netherlands	23	1.1k 1.3×	474 0.9×	393 1.0×	195 0.6×	92 0.4×	46	1.6k
Ludger Staib Germany	24	1.2k 1.4×	581 1.1×	430 1.1×	221 0.7×	129 0.6×	73	1.8k
Chung-Yuan Hu United States	21	2.1k 2.5×	1.1k 2.1×	710 1.7×	807 2.5×	106 0.5×	30	2.7k
Marcos V. Perini Australia	18	477 0.6×	567 1.1×	336 0.8×	126 0.4×	424 2.0×	97	1.2k
Thomas K. Weber United States	24	1.2k 1.4×	485 0.9×	346 0.8×	672 2.1×	91 0.4×	45	1.9k
Keiichiro Ishibashi Japan	19	809 0.9×	588 1.1×	522 1.3×	243 0.8×	105 0.5×	194	1.5k
Eran Sadot Israel	25	1.8k 2.1×	1.2k 2.3×	833 2.0×	158 0.5×	547 2.6×	70	2.8k

Countries citing papers authored by Jeffrey P. Meyers

Since Specialization

Citations

This map shows the geographic impact of Jeffrey P. Meyers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey P. Meyers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey P. Meyers more than expected).

Fields of papers citing papers by Jeffrey P. Meyers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey P. Meyers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey P. Meyers. The network helps show where Jeffrey P. Meyers may publish in the future.

Co-authorship network of co-authors of Jeffrey P. Meyers

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey P. Meyers. A scholar is included among the top collaborators of Jeffrey P. Meyers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey P. Meyers. Jeffrey P. Meyers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sinicrope, Frank A., Thomas R. Viggiano, Navtej Buttar, et al.. (2021). Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia. Cancer Prevention Research. 14(5). 573–580. 26 indexed citations

Bekaii‐Saab, Tanios, Fang‐Shu Ou, Daniel H. Ahn, et al.. (2019). Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. The Lancet Oncology. 20(8). 1070–1082. 181 indexed citations

Rose, Johnie, Chung Yin Kong, Gregory S. Cooper, et al.. (2019). Development and validation of a model to predict outcomes of colon cancer surveillance. Cancer Causes & Control. 30(7). 767–778. 2 indexed citations

Bekaii‐Saab, Tanios, Fang‐Shu Ou, Daniel M. Anderson, et al.. (2018). Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)â€“An ACCRU Network study.. Journal of Clinical Oncology. 36(4_suppl). 611–611. 31 indexed citations

Basch, Ethan, Amylou C. Dueck, Lauren J. Rogak, et al.. (2018). Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. Journal of Clinical Oncology. 36(31). 3120–3125. 53 indexed citations

McWilliams, Robert R., Nathan R. Foster, Michelle R. Mahoney, et al.. (2017). North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic‐based dosing of irinotecan, oxaliplatin, and capecitabine as first‐line therapy for patients with advanced small bowel adenocarcinoma. Cancer. 123(18). 3494–3501. 31 indexed citations

Zaanan, Aziz, Qian Shi, Julien Taı̈eb, et al.. (2017). Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy. JAMA Oncology. 4(3). 379–379. 89 indexed citations

Sinicrope, Frank A., Thomas C. Smyrk, Nathan R. Foster, et al.. (2016). Association of tumor infiltrating lymphocytes (TILs) with molecular subtype and prognosis in stage III colon cancers (CC) from a FOLFOX-based adjuvant chemotherapy trial.. Journal of Clinical Oncology. 34(15_suppl). 3518–3518. 4 indexed citations

Franko, Jan, Qian Shi, Jeffrey P. Meyers, et al.. (2016). Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. The Lancet Oncology. 17(12). 1709–1719. 434 indexed citations breakdown →

10.

Franko, Jan, Qian Shi, Jeffrey P. Meyers, et al.. (2016). Prognostic value of isolated peritoneal versus other metastatic sites in colorectal cancer (CRC) patients treated by systemic chemotherapy: Findings from 9,265 pts in the ARCAD database.. Journal of Clinical Oncology. 34(4_suppl). 656–656. 3 indexed citations

11.

Sinicrope, Frank A., Qian Shi, Carmen J. Allegra, et al.. (2016). Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers. JAMA Oncology. 3(4). 472–472. 74 indexed citations

12.

Shi, Qian, Frank A. Sinicrope, Daniel J. Sargent, et al.. (2015). Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial N0147).. Journal of Clinical Oncology. 33(15_suppl). 3590–3590. 2 indexed citations

13.

Zhao, Yujie, Nathan R. Foster, Jeffrey P. Meyers, et al.. (2014). A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group (NCCTG)-N0321. Journal of Thoracic Oncology. 10(1). 172–180. 38 indexed citations

14.

Dy, Grace K., Julian R. Molina, Yingwei Qi, et al.. (2014). NCCTG N0821 (Alliance): A Phase II First-Line Study of Pemetrexed, Carboplatin, and Bevacizumab in Elderly Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer With Good Performance Status. Journal of Thoracic Oncology. 9(8). 1146–1153. 6 indexed citations

15.

Saad, Everardo D., Dirkje W. Sommeijer, Qian Shi, et al.. (2014). Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database.. Journal of Clinical Oncology. 32(15_suppl). 3578–3578. 3 indexed citations

16.

Rule, William G., Nathan R. Foster, Jeffrey P. Meyers, et al.. (2014). Prophylactic cranial irradiation in elderly patients with small cell lung cancer: Findings from a North Central Cancer Treatment Group pooled analysis. Journal of Geriatric Oncology. 6(2). 119–126. 32 indexed citations

17.

Lieu, Christopher H., Lindsay A. Renfro, Aimery de Gramont, et al.. (2014). Association of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program. Journal of Clinical Oncology. 32(27). 2975–2982. 100 indexed citations

18.

Foster, Nathan R., Ann Farrell, Nguyet Le‐Lindqwister, et al.. (2013). Oral Cancer Chemotherapy Adherence and Adherence Assessment Tools: a Report from North Central Cancer Group Trial N0747 and a Systematic Review of the Literature. Journal of Cancer Education. 28(4). 770–776. 22 indexed citations

19.

Dy, Grace K., Sumithra J. Mandrekar, Garth D. Nelson, et al.. (2012). A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group Study N0528. Journal of Thoracic Oncology. 8(1). 79–88. 36 indexed citations

20.

Meyers, Jeffrey P.. (1983). Cancer Ward and the Literature of Disease. Twentieth Century Literature. 29(1). 54–54. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact